Insider Selling: Illumina, Inc. (NASDAQ:ILMN) EVP Sells 2,000 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) EVP Marc Stapley sold 2,000 shares of the company’s stock in a transaction on Thursday, October 26th. The shares were sold at an average price of $206.88, for a total value of $413,760.00. Following the completion of the transaction, the executive vice president now directly owns 34,579 shares in the company, valued at $7,153,703.52. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Marc Stapley also recently made the following trade(s):

  • On Tuesday, September 5th, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $205.93, for a total value of $411,860.00.
  • On Thursday, August 3rd, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $196.80, for a total transaction of $393,600.00.

Illumina, Inc. (NASDAQ:ILMN) opened at $206.05 on Wednesday. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. The firm has a market cap of $30,534.44, a P/E ratio of 61.15, a P/E/G ratio of 3.45 and a beta of 0.74. Illumina, Inc. has a 1 year low of $119.37 and a 1 year high of $214.50.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million during the quarter, compared to analysts’ expectations of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The firm’s quarterly revenue was up 17.6% on a year-over-year basis. During the same quarter last year, the company posted $0.97 EPS. analysts expect that Illumina, Inc. will post 3.75 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Insider Selling: Illumina, Inc. (NASDAQ:ILMN) EVP Sells 2,000 Shares of Stock” was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://weekherald.com/2017/11/15/insider-selling-illumina-inc-ilmn-evp-sells-2000-shares-of-stock.html.

A number of hedge funds have recently modified their holdings of ILMN. Advisory Services Network LLC boosted its position in Illumina by 13.0% in the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after buying an additional 89 shares during the period. Penserra Capital Management LLC boosted its position in Illumina by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock valued at $153,000 after buying an additional 102 shares during the period. Dupont Capital Management Corp purchased a new position in Illumina in the 3rd quarter valued at approximately $153,000. Paradigm Asset Management Co. LLC boosted its position in Illumina by 5.6% in the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after buying an additional 50 shares during the period. Finally, NN Investment Partners Holdings N.V. boosted its position in Illumina by 11.3% in the 2nd quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock valued at $171,000 after buying an additional 100 shares during the period. 92.70% of the stock is owned by institutional investors.

ILMN has been the topic of several recent research reports. reaffirmed an “outperform” rating and issued a $225.00 price target (up from $207.00) on shares of Illumina in a report on Tuesday, September 12th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $226.00 price target (up from $202.00) on shares of Illumina in a report on Monday, October 9th. Citigroup Inc. increased their target price on shares of Illumina from $180.00 to $220.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 25th. Bank of America Corporation increased their target price on shares of Illumina from $215.00 to $240.00 and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Finally, raised shares of Illumina from a “sell” rating to a “neutral” rating in a research note on Monday, October 23rd. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $200.88.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply